Overview

Evaluation in STEMI Patients Using FDY-5301

Status:
Not yet recruiting
Trial end date:
2024-07-31
Target enrollment:
Participant gender:
Summary
To assess the effect of FDY-5301 on cardiovascular mortality and acute heart failure events in subjects with an anterior STEMI undergoing pPCI.
Phase:
Phase 3
Details
Lead Sponsor:
Faraday Pharmaceuticals, Inc.